![Dikla Berko-Ashur](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Actieve functies van Dikla Berko-Ashur
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Sakura Bio
![]() Sakura Bio BiotechnologyHealth Technology Sakura Bio is a start-up company based in Jerusalem, Israel. Sakura Bio is developing an off-the-shelf, allogeneic T-cell therapy to fight cancer. The Israeli company's lead product, SAK-T (Super Activated Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. The company was founded by Dikla Berko-Ashur and Amnon Peled, with Dikla Berko-Ashur serving as CEO since incorporation. | Algemeen Directeur | 01-10-2022 | - |
Oprichter | 01-10-2022 | - |
Loopbaan van Dikla Berko-Ashur
Statistieken
Internationaal
Israël | 2 |
Operationeel
Chief Executive Officer | 1 |
Founder | 1 |
Sectoraal
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Sakura Bio
![]() Sakura Bio BiotechnologyHealth Technology Sakura Bio is a start-up company based in Jerusalem, Israel. Sakura Bio is developing an off-the-shelf, allogeneic T-cell therapy to fight cancer. The Israeli company's lead product, SAK-T (Super Activated Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. The company was founded by Dikla Berko-Ashur and Amnon Peled, with Dikla Berko-Ashur serving as CEO since incorporation. | Health Technology |
- Beurs
- Insiders
- Dikla Berko-Ashur
- Ervaring